Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors

LESSONS LEARNED. Pharmacokinetic results underscore that the vorolanib (X‐82) study design was successful without the need for further dose escalation beyond 400 mg once daily (q.d.). Therefore, the recommended dose of X‐82 as a single agent in patients with advanced cancer is 400 mg q.d. BACKGROUND...

Descripción completa

Detalles Bibliográficos
Autores principales: Bendell, Johanna C., Patel, Manish R., Moore, Kathleen N., Chua, Cynthia C., Arkenau, Hendrik‐Tobias, Dukart, Gary, Harrow, Kim, Liang, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459237/
https://www.ncbi.nlm.nih.gov/pubmed/30478190
http://dx.doi.org/10.1634/theoncologist.2018-0740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459237/
https://www.ncbi.nlm.nih.gov/pubmed/30478190
http://dx.doi.org/10.1634/theoncologist.2018-0740

Ejemplares similares